Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Björn Papke

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Molecular Biosystems|January 12, 2011
Precise measurement of protein interacting fractions with fluorescence lifetime imaging microscopyKirstin A Walther, Björn Papke, Maja B Sinn, et al.
Cell|April 15, 2014
KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transportMalte Schmick, Nachiket Vartak, Björn Papke, et al.
Nature|May 24, 2013
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signallingGunther Zimmermann, Björn Papke, Shehab Ismail, et al.
Cell Death and Differentiation|April 9, 2025
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibitionTamara Isermann, Kim Lucia Schneider, Florian Wegwitz, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibitionTamara Isermann, Kim Lucia Schneider, Florian Wegwitz, et al.
Science Signaling|July 22, 2025
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancerOleksandra Aust, Moritz R T Thiel, Eric Blanc, et al.
Nature Communications|April 21, 2016
Identification of pyrazolopyridazinones as PDEδ inhibitorsBjörn Papke, Sandip Murarka, Holger A Vogel, et al.
Cancer Research|December 18, 2021
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsClint A Stalnecker, Kajal R Grover, A Cole Edwards, et al.
Journal of Translational Medicine|August 16, 2024
Viscoelastic properties of colorectal liver metastases reflect tumour cell viabilityLisa-Marie Skrip, Simon Moosburner, Peter Tang, et al.
The Journal of Biological Chemistry|October 24, 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancerJ Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Molecular Biosystems|January 12, 2011
Precise measurement of protein interacting fractions with fluorescence lifetime imaging microscopyKirstin A Walther, Björn Papke, Maja B Sinn, et al.
Cell|April 15, 2014
KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transportMalte Schmick, Nachiket Vartak, Björn Papke, et al.
Nature|May 24, 2013
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signallingGunther Zimmermann, Björn Papke, Shehab Ismail, et al.
Cell Death and Differentiation|April 9, 2025
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibitionTamara Isermann, Kim Lucia Schneider, Florian Wegwitz, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibitionTamara Isermann, Kim Lucia Schneider, Florian Wegwitz, et al.
Science Signaling|July 22, 2025
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancerOleksandra Aust, Moritz R T Thiel, Eric Blanc, et al.
Nature Communications|April 21, 2016
Identification of pyrazolopyridazinones as PDEδ inhibitorsBjörn Papke, Sandip Murarka, Holger A Vogel, et al.
Cancer Research|December 18, 2021
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsClint A Stalnecker, Kajal R Grover, A Cole Edwards, et al.
Journal of Translational Medicine|August 16, 2024
Viscoelastic properties of colorectal liver metastases reflect tumour cell viabilityLisa-Marie Skrip, Simon Moosburner, Peter Tang, et al.
The Journal of Biological Chemistry|October 24, 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancerJ Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, et al.
Pageof 2